These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30869015)

  • 1. Pneumonia hospitalisation and case-fatality rates in older Australians with and without risk factors for pneumococcal disease: implications for vaccine policy.
    Dirmesropian S; Liu B; Wood JG; MacIntyre CR; McIntyre P; Karki S; Jayasinghe S; Newall AT
    Epidemiol Infect; 2019 Jan; 147():e118. PubMed ID: 30869015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the PCV 10 vaccination on community-acquired pneumonia hospitalisations after four years of its introduction into the Polish National Immunisation Programme: Follow-up study.
    Gajewska M; Lewtak K; Goryński P; Piotrowicz M; Urban E; Paradowska-Stankiewicz I; Rutyna A; Nitsch-Osuch A
    Vaccine; 2024 May; 42(13):3257-3262. PubMed ID: 38641493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.
    Ochoa-Gondar O; Vila-Corcoles A; Rodriguez-Blanco T; Gomez-Bertomeu F; Figuerola-Massana E; Raga-Luria X; Hospital-Guardiola I
    Clin Infect Dis; 2014 Apr; 58(7):909-17. PubMed ID: 24532544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and case fatality rates of community-acquired pneumonia and pneumococcal diseases among Korean adults: Catchment population-based analysis.
    Heo JY; Seo YB; Choi WS; Lee J; Yoon JG; Lee SN; Choi MJ; Noh JY; Ahn JY; Jeong HW; Cheong HJ; Kim WJ; Lee HY; Song JY
    PLoS One; 2018; 13(3):e0194598. PubMed ID: 29596444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring of community-acquired pneumonia hospitalisations before the introduction of pneumococcal conjugate vaccine into Polish National Immunisation Programme (2009-2016): A nationwide retrospective database analysis.
    Gajewska M; Goryński P; Paradowska-Stankiewicz I; Lewtak K; Piotrowicz M; Urban E; Cianciara D; Wysocki MJ; Książek A; Izurieta P
    Vaccine; 2020 Jan; 38(2):194-201. PubMed ID: 31653527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The burden of hospitalisations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003-2007).
    Gil-Prieto R; García-García L; Alvaro-Meca A; Méndez C; García A; de Miguel AG
    Vaccine; 2011 Jan; 29(3):412-6. PubMed ID: 21111780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015.
    LeBlanc J; ElSherif M; Ye L; MacKinnon-Cameron D; Ambrose A; Hatchette TF; Lang AL; Gillis HD; Martin I; Demczuk WH; LaFerriere C; Andrew MK; Boivin G; Bowie W; Green K; Johnstone J; Loeb M; McCarthy A; McGeer A; Semret M; Trottier S; Valiquette L; Webster D; McNeil SA
    BMJ Open Respir Res; 2020 Mar; 7(1):. PubMed ID: 32188585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of pneumococcal vaccination among older adults with pneumonia: findings from the Community Acquired Pneumonia Impact Study.
    Krueger P; St Amant O; Loeb M
    BMC Geriatr; 2010 Jun; 10():44. PubMed ID: 20591180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumonia hospitalisations in Scotland following the introduction of pneumococcal conjugate vaccination in young children.
    Nair H; Watts AT; Williams LJ; Omer SB; Simpson CR; Willocks LJ; Cameron JC; Campbell H
    BMC Infect Dis; 2016 Aug; 16():390. PubMed ID: 27506837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review.
    Torres A; Cillóniz C; Blasi F; Chalmers JD; Gaillat J; Dartois N; Schmitt HJ; Welte T
    Respir Med; 2018 Apr; 137():6-13. PubMed ID: 29605214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).
    Webber C; Patton M; Patterson S; Schmoele-Thoma B; Huijts SM; Bonten MJ;
    Vaccine; 2017 Mar; 35(9):1266-1272. PubMed ID: 28173960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumococcal serotypes in adult non-invasive and invasive pneumonia in relation to child contact and child vaccination status.
    Rodrigo C; Bewick T; Sheppard C; Greenwood S; Macgregor V; Trotter C; Slack M; George R; Lim WS
    Thorax; 2014 Feb; 69(2):168-73. PubMed ID: 24048505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recommendations for prevention of community-acquired pneumonia with bacteremia as the leading form of invasive pneumococcal infections in the population of people over 50 years of age and risk groups above 19 years of age].
    Albrecht P; Antczak A; Hryniewicz W; Skoczyńska A; Radzikowski A; Kedziora-Kornatowska K; Bernatowska E; Stompór T; Grodzicki T; Gyrczuk E; Imiela J; Jedrzejczak W; Windak A
    Pol Merkur Lekarski; 2014 Feb; 36(212):79-87. PubMed ID: 24720101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and Risk Factors for Invasive Pneumococcal Disease and Community-acquired Pneumonia in Human Immunodeficiency Virus-Infected Individuals in a High-income Setting.
    Garcia Garrido HM; Mak AMR; Wit FWNM; Wong GWM; Knol MJ; Vollaard A; Tanck MWT; Van Der Ende A; Grobusch MP; Goorhuis A
    Clin Infect Dis; 2020 Jun; 71(1):41-50. PubMed ID: 31634398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia.
    Rodrigo C; Bewick T; Sheppard C; Greenwood S; Mckeever TM; Trotter CL; Slack M; George R; Lim WS
    Eur Respir J; 2015 Jun; 45(6):1632-41. PubMed ID: 25792633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid Decrease in Rates of Hospitalization Resulting From Invasive Pneumococcal Disease and Community-Acquired Pneumonia in Children Aged <60 Months After 13-Valent Pneumococcal Conjugate Vaccine Introduction in Argentina.
    López EL; Glatstein E; Ezcurra GC; Iacono M; Teplitz E; Garnero AV; Lazzarini DL; Vázquez M; Contrini MM
    J Pediatric Infect Dis Soc; 2018 Feb; 7(1):30-35. PubMed ID: 28339727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study.
    Vila-Corcoles A; Ochoa-Gondar O; de Diego C; Satue E; Aragón M; Vila-Rovira A; Gomez-Bertomeu F; Magarolas R; Figuerola-Massana E; Raga X; Perez MO; Ballester F
    BMC Infect Dis; 2018 Apr; 18(1):196. PubMed ID: 29699550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 13-Valent vaccine serotype pneumococcal community acquired pneumonia in adults in high clinical risk groups.
    Daniel P; Rodrigo C; Bewick T; Sheppard C; Greenwood S; McKeever TM; Trotter C; Lim WS
    Vaccine; 2018 Mar; 36(12):1614-1620. PubMed ID: 29439865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of pneumococcal polysaccharide vaccine in older adults.
    Jackson LA; Neuzil KM; Yu O; Benson P; Barlow WE; Adams AL; Hanson CA; Mahoney LD; Shay DK; Thompson WW;
    N Engl J Med; 2003 May; 348(18):1747-55. PubMed ID: 12724480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults.
    Chalmers JD; Campling J; Dicker A; Woodhead M; Madhava H
    BMC Pulm Med; 2016 May; 16(1):77. PubMed ID: 27169895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.